The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF)
buprenorphine/naloxone combination tablet administration and determine whether outcomes are
improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one
in which take-home doses are given on intervening days.
Mon/Wed/Fri dosing with the 8 mg buprenorphine/naloxone tablet is as safe and effective as
daily dosing and is preferred by patients to daily dosing. Multiple doses of the combination
tablet (e.g. 16mg, 24mg) are well tolerated by patients. A 3 day schedule with take-outs is
as effective as a 3-day schedule in which all medication is ingested at the clinic
Individual must be currently dependent and meet FDA criteria for narcotic maintenance
treatment. Co-morbid substance abuse or dependence disorders may also be present.
Individuals must be healthy despite drug dependency.
Individuals with evidence of an active Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) Axis I psychiatric disorder (e.g., psychosis, manic-depressive illness,
organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular
disease) or pregnant female subjects are excluded from study participation.